Novartis India has posted a net profit of Rs 318 m for 2QFY03, a rise of 48% over corresponding quarter last year. As against Rs 216 m in the corresponding quarter last year. However, the figures for the year are not comparable as the company demerged its agrochemical business, which resulted in this sharp decline in turnover and profits. The company also decided to exit the lens and lens care business of CibaVision with effect from December 2000 due to unviability of the same. The other income has also increased sharply by 276%, which has further aided bottomline.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
Pharma sales for the period closed at Rs 811 m registering a growth of 19% over the previous period. Growth was impacted by lower sales of the company’s transplant and oncology range of products. In late 2001, the company has carved out the Biochemie segment from the existing pharma business to align the portfolio with that of the parent company. The Biochemie sector primarily focuses on the therapeutic segments of Anti-TB, Anti-DUB (gynaecology) Anti-histamines, Antibiotics, Anti-ulcerants, Anti-diabetes and Cardiovascular. This sector registered sales of Rs 289 m declining by 8% compared to same period previous year. On a like to like basis (pharma and Biochemie division consolidated), the company has grown 10%, underperforming industry growth rates due to absence of new products.
Consumer Healthcare achieved good growth over last year largely driven by its popular OTC brand Calcium Sandoz. An encouraging growth in animal health care business was primarily driven by intensive marketing efforts in cattle and poultry segments and addition of three new licenced-in products in the cattle segment.
Novartis has initiated several measures to put growth on the fast track. It has launched a strategy to revitalise its mature product portfolio by introducing product extensions and variants. Innovative marketing focused on product customisation and disease administration would supplement Novartis efforts in this
direction. Novartis has also identified the high growth CVS segment as a focus area where it proposes to launch brands from the parent portfolio. Introduction of new products will be the key growth driver for Novartis. Given Novartis AG’s strong pipeline of 69 drugs under development, one can expect a further ramp up in product introductions in future. NIL also plans to enter into co-marketing and alliances besides brand acquisitions to step up the growth momentum.brands and new introductions to drive growth.
At the current market price of Rs 213 , the stock trades at 6x 2QFY02 earnings. The future growth of the company depends on the success of the new products launched recently.We think the worry at the moment is the uncertainty over a new price control regime that is likely to bring the flagship brands of Novartis − Voveran, Regestrone and Otrivin − under price control. These brands accounted for 28% of retail sales of the company in the past 12 months. We estimate that this would translate into 16% of total sales or Rs760m revenues. In the past, when a new drug was brought under price control, the government has ordered a substantial downward revision in price. Assuming a modest 20% price cut would mean a loss of sales in FY03E of Rs167m and lower profit estimate of Rs602m against Rs753m currently. Such a 20% fall in profits would also affect our valuation of the company.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407